| Sumario: | The article discusses the increasing rates of placebo responses in clinical trials for psoriasis and psoriatic arthritis, particularly noting that these rates are higher in low-income countries compared to high-income countries. This trend complicates the ability to identify effective treatments, as the active treatment response does not keep pace with placebo responses in psoriatic arthritis trials. The article also explores factors influencing placebo responses, such as patient expectations and the method of placebo administration, and suggests strategies to minimize these responses in trials. Additionally, it highlights emerging approaches like target trial emulation as alternatives to traditional randomized trials, aiming to address limitations in trial design and patient diversity.
|
|---|